Along with HbA1c, glucose variability (GV) in type 1 diabetes (T1DM) is increasingly regarded as a primary marker of glycemic control. In our past studies we identified physiological and behavioral correlates of GV and successfully tested a biobehavioral intervention reducing simultaneously HbA1c and the risk for hypoglycemia. A signature characteristic of this research was the development of, and the reliance upon, sophisticated computer models and advanced technology, e.g. the only to date computer simulator of the human metabolism accepted by the FDA as a substitute to animal studies and the new Diabetes Assistant (DiAs) platform, which was used in the first [Worldwide] trials of ambulatory artificial pancreas. We now propose to continue our investigations by focusing on the following fundamental hypothesis: Glucose variability in T1DM is triggered by behavioral events (e.g. meals, insulin injection) that challenge the metabolic system. The timing and the magnitude of the behavioral challenges, and the ability of the metabolic mechanisms to absorb them, determine the magnitude of GV. This process develops in a certain time frame, and can be accelerated by inadequate treatment, or attenuated by precise timing and dosing of bio- behavioral control. The testing of this hypothesis will proceed in three phases: Phase 1 (triggers of GV) will use our extensive database to design an Integrated Model of Glucose Variability (IMGV), which will: (I) help understand the timing and the magnitude of system destabilization with mistimed or unbalanced treatment, and (ii) assist the design of an optimal biobehavioral intervention to be employed in Phase 3 by extensive in silicon experiments clarifying the timing and the precursors of system stabilization. Phase 2 (mechanisms of GV) will use a combination of diaries, continuous glucose monitoring, and insulin pump records in the field, augmented by hospital-based human lab studies, which will clarify key relationships between behavioral challenges, physiological glucoregulatory mechanisms, and GV. Phase 3 (control of GV) will test, using DiAs in a randomized cross-over study, the effectiveness of a novel stepwise biobehavioral intervention designed to gradually attenuate GV. This treatment will be tested in insulin pump users at poor glycemic control (HbA1c>8.0%) and/or at risk for hypoglycemia (those with history of severe hypoglycemia), and is expected to be superior to standard pump therapy in terms of reduction of GV. In summary, this project will demonstrate that: (I) in silico experiments combined with observational and human lab studies enhance hypothesis formulation/testing, and result in efficient treatment design;(ii) cutting-edge artificial pancrea technology translated for everyday use is superior to state-of-the art current treatments.

Public Health Relevance

Biobehavioral Triggers, Mechanisms, and Control of Glucose Variability in T1DM Project Narrative Glucose variability (GV) in type 1 diabetes is increasingly regarded as a primary marker of glycolic control, potentially responsible, along with chronic hyperglycemia reflected by HbA1c, for a host of diabetes complications. Research must therefore focus on (I) the triggers and the mechanisms leading to increased GV, and (ii) methods for control of GV. We now propose an interdisciplinary project using human laboratory and field studies and sophisticated computer simulation to elucidate the interplay between behavioral triggers and physiological mechanisms of GV, and to design and test a stepwise behavioral-feedback intervention specifically targeting reduction of GV in patients'natural environment. In is envisioned that this interdisciplinary approach will enhance hypothesis formulation and testing, and will promote efficient in-silicon treatment designs that can be translated to other research studies and into the clinical practice.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Behavioral Medicine, Interventions and Outcomes Study Section (BMIO)
Program Officer
Arreaza-Rubin, Guillermo
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Virginia
Schools of Medicine
United States
Zip Code
Kovatchev, Boris; Cobelli, Claudio (2016) Glucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes. Diabetes Care 39:502-10
Kovatchev, Boris P; Breton, Marc D (2015) Hemoglobin A1c and Self-Monitored Average Glucose: Validation of the Dynamical Tracking eA1c Algorithm in Type 1 Diabetes. J Diabetes Sci Technol 10:330-5
Kovatchev, Boris P; Patek, Stephen D; Ortiz, Edward Andrew et al. (2015) Assessing sensor accuracy for non-adjunct use of continuous glucose monitoring. Diabetes Technol Ther 17:177-86
Kovatchev, Boris P (2015) Measures of Risk and Glucose Variability in Adults Versus Youths. Diabetes Technol Ther 17:766-9
Fabris, Chiara; Patek, Stephen D; Breton, Marc D (2015) Are Risk Indices Derived From CGM Interchangeable With SMBG-Based Indices? J Diabetes Sci Technol 10:50-9
Lv, Dayu; Kulkarni, Sandip D; Chan, Alice et al. (2015) Pharmacokinetic Model of the Transport of Fast-Acting Insulin From the Subcutaneous and Intradermal Spaces to Blood. J Diabetes Sci Technol 9:831-40
Lv, Dayu; Breton, Marc D; Farhy, Leon S (2013) Pharmacokinetics modeling of exogenous glucagon in type 1 diabetes mellitus patients. Diabetes Technol Ther 15:935-41
Farhy, Leon S; Chan, Alice; Breton, Marc D et al. (2012) Association of Basal hyperglucagonemia with impaired glucagon counterregulation in type 1 diabetes. Front Physiol 3:40
Chan, A; Barrett, E J; Anderson, S M et al. (2012) Muscle microvascular recruitment predicts insulin sensitivity in middle-aged patients with type 1 diabetes mellitus. Diabetologia 55:729-36
Kovatchev, Boris P; Mendosa, Pamela; Anderson, Stacey et al. (2011) Effect of automated bio-behavioral feedback on the control of type 1 diabetes. Diabetes Care 34:302-7

Showing the most recent 10 out of 82 publications